BDMD

Baird Medical Investment Holdings Limited
CAPPED RATING

Baird Medical Investment Holdings Limited, together with its subsidiaries develops and sells microwave ablation medical devices for minimally invasive tumor treatment in China. The company's medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Baird Medical Investment Holdings Limited was founded in 2012 and is headquartered in Guangzhou, China.

Baird Medical Investment Holdings Limited (BDMD) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Momentum (F). The rating has held at C+ for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B
Factor Score 3.4 / 5.0
Growth
B
Factor Score 3.2 / 5.0
Profitability
A-
Factor Score 4.0 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.8
EV / EBITDA -1.6
Rev Growth YoY 24.6%
Gross Margin 85.6%
Price Return 3M -90.2%
Price Return 12M -91.6%
Catalyst Signal 0.00
Market Cap $3.4M
TTM Revenue $24.5M
Price / Sales 0.1
ROE -46.0%

Historical Factor Score Progression

Held C+ for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.4) B (3.2) A- (4.0) F (0.6) C+ (2.6) C+ (2.8)
2026-11-10 B (3.4) B (3.2) A- (4.0) D- (0.9) C+ (2.6) C+ (2.8)
2026-11-03 B (3.4) B (3.2) A- (4.0) D- (0.7) C+ (2.7) C+ (2.8)
2026-10-27 B (3.4) B- (3.1) A- (4.0) D- (0.9) C+ (2.6) C+ (2.8)
2026-10-20 B (3.4) B- (3.1) A- (4.0) D- (1.1) C+ (2.6) C+ (2.8)
Page 1 of 4